Skip to main content
SpringerLink
Log in

Zur Frage der Erhaltungstherapie bei Patientinnen mit metastasierendem Mammakarzinom in Remission

  • Conference paper
Mammakarzinome. Neue Perspektiven experimenteller und klinischer Therapieforschung

  • 18 Accesses

Zusammenfassung

Obwohl sich bei der Behandlung von Patientinnen mit fortgeschrittenem metastasierendem Mammakarzinom die Frage, wie therapeutisch bei Erreichen einer stabilen Remission verfahren werden soll, immer wieder stellt, gibt es bis heute keine systematischen Untersuchungen zum Thema der Erhaltungstherapie.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Brambilla C, Delena M, Rossi A, Valagussa P, Bonadonna G (1976) Response and survival in advanced breast cancer after two non-cross-resistant combinations. Br Med J 1:801–804

    Article  PubMed  CAS  Google Scholar 

  2. Bull JM, Tormey DC, Li SH, Carbone PP, Falkson G, et al. (1978) A Randomized Comparative Trial of Adriamycin versus Methotrexate in Combination Drug Therapy. Cancer 41:1649–1657

    Article  PubMed  CAS  Google Scholar 

  3. Campbell FC, Blarney RW, Elston CW, Nicholson RI, Griffiths K, et al. (1979) Oestrogenreceptor status and sites of metastasis in breast cancer. Cancer 44:665–670

    Article  Google Scholar 

  4. Carbone PP, Bauer M, Band P, Tormey D (1977) Chemotherapy of disseminated breast cancer. Cancer 39:2916–2922

    Article  PubMed  CAS  Google Scholar 

  5. Cocconi G, De Lisi V, Boni C, Mori P, Malacarne P, et al. (1983) Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer. Cancer 51:581–588

    Article  PubMed  CAS  Google Scholar 

  6. Creech RH, Catalano RB, Harris DT, Engstrom PF, Grotzinger PR (1979) Low Dose Chemotherapy of Metastatic Breast Cancer with Cyclophosphamide, Adriamycin, Methotrexate, 5-Fluorouracil (CAMF) versus sequential Cyclophosphamide, Methotrexate, 5-Fluorouracil (CMF) and Adriamycin. Cancer 43:51–59

    Article  PubMed  CAS  Google Scholar 

  7. Decker DA, Ahmann DL, Bisel HF, Edmonson JH, Hahn RG, et al. (1979) Complete responders to chemotherapy in metastatic breast cancer. J Amer med Assoc 242:2075–2079

    Article  CAS  Google Scholar 

  8. Engelsman E (1983) Therapy of advanced breast cancer: a review. Eur J Cancer Clin Oncol 19:1775–1778

    Article  PubMed  CAS  Google Scholar 

  9. Falkson G, Falkson HC (1981) A five-drug combination in the treatment of metastatic breast cancer. Cancer Clin Trials 4:81–85

    PubMed  CAS  Google Scholar 

  10. Falkson G, Gelman RS, Tormey DC, Cummings FJ, Carbone PP, et al. (1985) The Eastern Cooperative Oncology Group experience with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer. Cancer 56:219–224

    Article  PubMed  CAS  Google Scholar 

  11. Feldman L, Hortogayi G, Buzdar A, Blumenschein G, Haynie T (1984) Duration of chemotherapy to achieve complete remission (CR). A prognostic factor in metastatic breast cancer (MBC). ASCO-Abstract C-475

    Google Scholar 

  12. Fey MF, Brunner KW, Sonntag RW (1981) Prognostic factors in metastatic breast cancer. Cancer Clin Trials 4:237–247

    PubMed  CAS  Google Scholar 

  13. Fischer J, Rose CJ, Rubens RD (1982) Duration of complete response to chemotherapy in advanced breast cancer. Eur J Cancer Clin Oncol 18:747–754

    Article  PubMed  CAS  Google Scholar 

  14. Freedman LS, Edwards DN, McConnell EM, Downham DY (1979) Histological grade and other prognostic factors in relation to survival of patients with breast cancer. Br J Cancer 40:44–55

    Article  PubMed  CAS  Google Scholar 

  15. Gewirtz AM, Cadman E (1981) Preliminary Report on the Efficacy of Séquentiel Methotrexate and 5-Fluorouracil in Advanced Breast Cancer. Cancer 47:2552–2555

    Article  PubMed  CAS  Google Scholar 

  16. Henderson C (1983) Chemotherapy of breast cancer. Cancer 51:2553–2559

    Article  PubMed  CAS  Google Scholar 

  17. Henderson C, Canellos GP (1980) Cancer of the breast. The past decade (second of two parts). N Engl J Med 302:78–90

    Article  PubMed  CAS  Google Scholar 

  18. Henderson C, Gelman R, Canellos GP, Frei E III Prolonged disease-free survival in advanced breast cancer treated with „super-CMF“Adriamycin: an alternating regimen employing high-dose Methotrexate with citrovorum factor rescue. Cancer Treat Rep 65 (Suppl 1):65–75

    Google Scholar 

  19. Hirshaut Y, Kesselheim H (1983) Prolonged remissions of metastatic breast cancer achieved with a six-drug regimen of relatively low toxicity. Cancer 51:1998–2004

    Article  PubMed  CAS  Google Scholar 

  20. Howell A, Barnes DM, Harland RNL, Redford J, Bramwell VHC, et al. (1984) Steroid-hormone receptors and survival after first relapse in breast cancer. Lancet 1:588–591

    Article  PubMed  CAS  Google Scholar 

  21. Karabali-Dalamaga S, Souhami RL, Ottiggins NJ, Soumilas A, Clark CG (1978) Natural history and prognosis of recurrent breast cancer. Br Med J 2:730–733

    Article  PubMed  CAS  Google Scholar 

  22. Legha SS, Buzdar AU, Smith TL, Hortobagyi GN, Swenerton KD, et al. (1979) Complete remissions in metastatic breast cancer treated with combination drug therapy. Ann Int Med 91:847–852

    PubMed  CAS  Google Scholar 

  23. Manni A, Trujillo JE, Pearson OH (1980) Sequential use of endocrine therapy and chemotherapy for metastatic breast cancer: Effects on survival. Cancer Treat Rep 64:111–116

    PubMed  CAS  Google Scholar 

  24. Mattson W, Eyben FV, Hallstein L, Bjelkengren G (1982) A phase II study of combined 5-Fluorouracil and Mitomycin C in advanced breast cancer. Cancer 49:217–220

    Article  Google Scholar 

  25. Mattsson W, Arwidi A, von Eyben F, Lindholm CE (1979) Combination chemotherapy in advanced postmenopausal mammary carcinoma. Acta Radiol Oncol 18:431–444

    Article  CAS  Google Scholar 

  26. Meyer JS, Rao BR, Stevens SC, White WL (1977) Low indicence of estrogen receptor in breast carcinoma with rapid rates of cellular replications. Cancer 40:2290–2298

    Article  PubMed  CAS  Google Scholar 

  27. Muss HB, White DR, Richards F, Cooper MR, Stuart JJ, et al. (1978) Adriamycin versus Methotrexate in Five-Drug Combination Chemotherapy for Advanced Breast Cancer. Cancer 42:2141–2148

    Article  PubMed  CAS  Google Scholar 

  28. Powles TJ, Smith IE, Ford HT, Coombes RC, Jones JM, et al. (1980) Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer. Lancet I:580–582

    Article  Google Scholar 

  29. Ross MB, Buzdar AU, Smith TL, Eckles N, Hortobagyi GN, et al. (1985) Improved survival of patients with metastatic breast cancer receiving combination chemotherapy. Cancer 55:541–546

    Article  Google Scholar 

  30. Rossof AH, Gelman R, Creech RH (1982) Randomized evaluation of combination chemotherapy vs. observation alone following response or stabilization after oophorectomy for metastatic breast cancer in premenopausal women. Amer J Clin Oncol 5:253–259

    Article  CAS  Google Scholar 

  31. Rubens RD, Begent RHJ, Knight RK, Sexton SA, Hayward JL (1978) Combined cytotoxic and progestogen therapy for advanced breast cancer. Cancer 42:1680–1686

    Article  PubMed  CAS  Google Scholar 

  32. Salmon SE, Jones SE (1979) Untersuchungen der Kombination Adriamycin und Cyclophosphamid (allein oder mit anderen Substanzen) zur Behandlung des Mammakarzinoms. Onkologie 2:2

    Article  Google Scholar 

  33. Samaan NA, Buzdar AU, Aldinger KA, Schultz PN, Yang KP, et al. (1981) Estrogen receptor: a prognostic factor in breast cancer. Cancer 47:554–560

    Article  PubMed  CAS  Google Scholar 

  34. Silverstrini R, Daidone MG, DiFronzo G (1979) Relationship between proliferative activity and estrogen receptors in breast cancer. Cancer 44:665–670

    Article  PubMed  CAS  Google Scholar 

  35. Spremulli EN, Dexter DL (1983) Human tumor cell heterogeneity and metastasis. J Clin Oncol 1:496–509

    PubMed  CAS  Google Scholar 

  36. Stewart JF, Rubens RD, Millis RR, King RJB, Hayward JL (1983) Steroid receptors and prognosis in operable (stage I and II) breast cancer. Eur J Cancer Clin Oncol 19:1381–1387

    Article  PubMed  CAS  Google Scholar 

  37. Straus MJ, Moran RE (1980) The cell cycle kinetics of human breast cancer. Cancer 46:2634–2639

    Article  PubMed  CAS  Google Scholar 

  38. Swenerton KD, Legha SS, Smith T, Hortogagyi GN, Gehan EA, et al. (1979) Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 39:1552–1562

    PubMed  CAS  Google Scholar 

  39. Valagussa P, Brambilla C, Bonadonna G (1979) Advanced breast cancer: are the traditional stratification parameters still of value when patients are treated with combination chemotherapy. Eur J Cancer 15:565–571

    PubMed  CAS  Google Scholar 

  40. Wander HE (1981) Indikationen von Adriamycin beim metastasierenden Mammakarzinom. Beitr Onkol 9:140–149

    Google Scholar 

  41. Wander HE, Nagel GA (1984) Nadir-adapted polychemotherapy of metastatic breast cancer (mbc). Verh Dt KrebsGes 5:595

    Google Scholar 

  42. Weigand RA (1984) Cellular heterogeneity in human breast cancer. AACR Abstract 214

    Google Scholar 

  43. WHO Handbook for reporting results of cancer treatment (1979). SHO Offset Publication No. 48 Geneva

    Google Scholar 

Download references

Authors
  1. G. A. Nagel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H.-E. Wander
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H.-H. Bartsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J.-H. Beyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. W. Holtkamp
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D. Meyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P. Schuff-Werner
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C. Unger
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Abteilung Hämatologie/Onkologie, Medizinische Universitätsklinik, Robert-Koch-Straße 40, D-4300, Göttingen, Deutschland

    G. A. Nagel

Rights and permissions

Reprints and permissions

Copyright information

© 1986 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Nagel, G.A. et al. (1986). Zur Frage der Erhaltungstherapie bei Patientinnen mit metastasierendem Mammakarzinom in Remission. In: Nagel, G.A. (eds) Mammakarzinome. Neue Perspektiven experimenteller und klinischer Therapieforschung. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-71041-4_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-71041-4_10

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-71042-1

  • Online ISBN: 978-3-642-71041-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation